Evidence map›Paper›PMID 39060686›Full record

ArticleAnnals of surgical oncology2024

Surgical Outcome in Retroperitoneal Sarcoma Surgery: Accuracy of P-POSSUM, ACS-NSQIP, and Inflammatory Biomarkers Prognostic Index (IBPI) Risk-Calculators for Prediction of Severe and Overall Morbidity.

Michela Angelucci, Marco Baia, Marilù Garo, Rossana Alloni, Dario Callegaro, Chiara Pagnoni, Stefano Radaelli, Chiara Colombo, Sandro Pasquali, Alessandro Gronchi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michela Angelucci *U.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.
Marco Baia *S.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. marco.baia@istitutotumori.mi.it.ORCID http://orcid.org/0000-0001-8594-6759
Marilù GaroIndependent Research, Rome, Italy.
Rossana AlloniDepartment of Medicine and Surgery, Università Campus BioMedico, Rome, Italy.
Dario CallegaroS.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Chiara PagnoniU.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.
Stefano RadaelliS.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Chiara ColomboS.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sandro PasqualiMolecular Pharmacology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Alessandro GronchiS.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Sergio ValeriU.O.S. Chirurgia dei Sarcomi dei Tessuti Molli, Fondazione Policlinico Campus BioMedico, Rome, Italy.
Marco FioreS.C. Chirurgia dei Sarcomi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRetroperitoneal sarcoma often requires comprehensive resection, leading to severe postoperative morbidity. The lack of disease-procedure specific tools for morbidity risk and the questionable accuracy of existing tools (ACS-NSQIP and P-POSSUM) in RPS surgery drove this study to assess these calculators' accuracy.

methodsRetrospective analysis of primary RPS cases undergoing surgery at two sarcoma-referral centers was conducted. Predicted morbidity/mortality rates at 90 days postsurgery, classified by Clavien-Dindo (CD) and Comprehensive Complication Index (CCI), were compared with observed data. Accuracy was assessed by Brier Score and area under the curve (AUC). Inflammatory Biomarkers Prognostic Index (IBPI) also was tested.

resultsA total of 567 patients (median age 62 years; 53.6% male) with a median of four resected organs were included. 59% experienced surgical complications by 90 days postoperation, graded CD ≥ 3 in 30.5%, median CCI 20.9, with a mortality rate of 1.6% (8/567). Reoperation was required in 68 of 567 patients (12%). Thirty-day mortality was 1.1%. Severe complications occurred after 30th postoperative day in 3.5% cases. ACS-NSQIP predicted below-average complication for 65.1%, average for 16.9%, and above-average for 18% of patients. P-POSSUM predicted a 66% rate of morbidity and 4% mortality. None of the prediction tools were accurate, with Brier scores ranging 0.155-0.231 and no AUC ≥ 0.7. IBPI accuracy for predicting severe infective complication was low (AUC 0.58, Brier 0.161).

conclusionsThe significant morbidity burden after MVR necessitates reliable evaluation, especially in frail patients. Given the limitations of ACS-NSQIP and P-POSSUM, a dedicated prediction tool for perioperative events in RPS candidates for MVR needs urgent development.

Indexed as

Postoperative ComplicationsRetroperitoneal NeoplasmsSarcomaAdultAgedBiomarkersBiomarkers, TumorFemaleFollow-Up StudiesHumansInflammationMaleMiddle AgedMorbidityPrognosisRetrospective StudiesBiomarkersBiomarkers, Tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.